{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-030051","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2023-08-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.961667+00:00","generated_at":"2026-06-11T04:05:42.790414+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bioxytran receives FDA clearance to initiate clinical trials for ProLectin-M in COVID-19","bullets":["FDA cleared IND No. 153742 for ProLectin-M, an oral galectin antagonist for mild-to-moderate COVID-19.","ProLectin-M is Bioxytran's first program to enter the clinic; it aims to showcase broad-spectrum antiviral potential.","Prior phase 2 trial showed 100% PCR-negative by day 7 and 88% by day 3; no viral rebounds.","Company preparing for Phase 3 to seek regulatory approval of ProLectin-M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-030051","json":"https://secwatch.observer/filing/0001493152-23-030051.json","markdown":"https://secwatch.observer/filing/0001493152-23-030051.md","text":"https://secwatch.observer/filing/0001493152-23-030051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315223030051/0001493152-23-030051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315223030051/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T04:05:42.790414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}